What happens when AI touches every role, every day, in clinical development? Stephen Pyke of Parexel, in conversation with Nagaraja Srivatsan, highlights why preparing teams early is essential to unlock their full potential. trials?youtube.com/watch?v=gNTNJh…

Todd Harris Tyra Biosciences discusses the company’s experimental oral medicine for achondroplasia, studies conducted to date, and why he believes it will offer competitive advantages over existing therapies. Global Genes #RARECast globalgenes.org/raredaily/taki…

Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. linkedin.com/pulse/extendin…

Marc Salzberg Airway Therapeutics discusses the company’s experimental therapy zelpultide alfa to treat preterm infants with a rare lung disease, why it’s a pipeline-in-a-product, and its development path forward. thebioreport.podbean.com/e/scratching-t…

Amélie Lothe, global medical community head for rare epilepsies at UCB US, discusses the need to look beyond seizures to view developmental and epileptic encephalopathies as complex neurodevelopmental conditions. Global Genes #RARECast globalgenes.org/raredaily/the-…

Kristin McKay Project Alive discusses the need for new therapies for Hunter syndrome, the importance of early detection, and the patient community’s concerns with regulatory delays in approving needed treatments. Global Genes #RARECast globalgenes.org/raredaily/a-ca…

.@drewendy.bsky.social Hoover Institution Stanford University discusses China’s all-of-nation strategy, how the US has misallocated research dollars, and why a cultural embrace of biotechnology will be critical for the success of either country. thebioreport.podbean.com/e/why-the-unit…

Laura Russo, U.S. patient engagement lead for Pfizer Inc. , discusses how the company’s patient-facing teams work to bridge health systems and patient communities to improve access and care. Global Genes #RARECast globalgenes.org/raredaily/impr…

The Rwanda FDA approved Bio Usawa lnc 's BioUcenta, a biosimilar of Lucentis. It is the first biosimilar ranibizumab approved in Africa and represents the first major regulatory milestone for Bio Usawa. globenewswire.com/news-release/2…

Stacy Lindborg, CEO of Imunon, discusses the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease. thebioreport.podbean.com/e/changing-the…

Aaron Cohen, Head of Research Oncology, Clinical Data at Flatiron Health , joins Amar Drawid, on Life Sciences DNA to explore how large language models are transforming oncology research. youtube.com/watch?v=W-Gq6Y…

Philippa Ward discusses her journey as the mother of a child diagnosed with tuberous sclerosis complex, the challenges posed by the condition’s complexities, and how she found both a community and her own voice as an advocate. Global Genes #RARECast globalgenes.org/raredaily/lear…

John Hoekman Junevity discusses the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform, and its lead programs targeting type 2 diabetes and obesity. thebioreport.podbean.com/e/hitting-the-…

Prarthana Khanna, VP of corporate business development and strategy for Vico Therapeutics, discusses Huntington's disease, the company’s experimental ASO, and why it has the potential to address multiple neurological diseases. Global Genes #RARECast globalgenes.org/raredaily/taki…

Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. linkedin.com/pulse/why-us-m…

Brian Weitzner openfold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold. thebioreport.podbean.com/e/an-ai-collab…

Jeffrey Brown CSO of TriNetX, discusses how real-world data can address common challenges in rare disease research, the hurdles that need to be addressed, and how advances in AI could revolutionize rare disease research. @globalgenes #RARECast globalgenes.org/raredaily/tran…

Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential. thebioreport.podbean.com/e/a-hub-and-sp…

Ronel Veksler, co-founder and CEO of PromiseBio discusses his company’s AI-enabled proteomics platform, and how post-translational modifications of proteins represent a new frontier for precision medicine in autoimmune diseases. youtube.com/watch?v=jeJhRF…

Andrew Rosen National Ataxia Foundation discusses the critical role of patient-led organizations in early-stage research and advocacy, and the recent surge of therapeutic activity targeting these neurodegenerative conditions. Global Genes #RARECast globalgenes.org/raredaily/chan…